The PI3K/AKT/mTOR pathway was estimated to be upregulated in up to 70% of all breast cancers, including TNBC (3) but inhibitors of this pathway have been approved so far only for ER+ breast cancer and have not shown clinical efficacy in TNBC. Here, ESR1 is linked to breast carcinoma.